The single-arm phase 2 START-FIT trial investigated sequential TACE and SBRT followed by anti-PD-L1 avelumab in patients with locally advanced hepatocellular carcinoma who were unsuitable for curative treatment (NCT03817736) [109]. Here, CD274 is linked to hepatocellular carcinoma.